TURNOVER (x1000 EUR)
NET PROFIT (x1000 EUR)
EMPLOYEES
Oncopeptides AB
Closing information (x1000 EUR)
| Closing information | 2024/12 (consolidated) | 2023/12 (consolidated) | 2022/12 (consolidated) |
| Turnover |
2,755
|
3,271
|
751 |
| Financial expenses |
1,446
|
521
|
79 |
| Earnings before taxes |
-24,743
|
-22,391
|
-30,344 |
| EBITDA |
-24,466
|
-21,846
|
-29,849 |
| Total assets |
21,259
|
21,483
|
34,626 |
| Current assets |
18,899
|
18,286
|
32,712 |
| Current liabilities |
4,471
|
4,049
|
7,474 |
| Equity capital |
4,726
|
5,117
|
26,445 |
| - share capital |
2,082
|
947
|
942 |
| Employees (average) |
66
|
52
|
57 |
Financial ratios
| Fiscal year | 2024/12 (consolidated) | 2023/12 (consolidated) | 2022/12 (consolidated) |
| Solvency |
22.2%
|
23.8%
|
76.4% |
| Turnover per employee |
42
|
63
|
13 |
| Profit as a percentage of turnover |
-898.1%
|
-684.5%
|
-4040.5% |
| Return on assets (ROA) |
-109.6%
|
-101.8%
|
-87.4% |
| Current ratio |
422.7%
|
451.6%
|
437.7% |
| Return on equity (ROE) |
-523.6%
|
-437.6%
|
-114.7% |
| Change turnover |
-405
|
2,518
|
-9,879 |
| Change turnover % |
-13%
|
334%
|
-93% |
| Chg. No. of employees |
14
|
-5
|
-172 |
| Chg. No. of employees % |
27%
|
-9%
|
-75% |
Total value of public sale
| Fiscal year | 2024/12 (consolidated) | 2023/12 (consolidated) | 2022/12 (consolidated) |
| Total value of public sale |
0
|
0
|
0 |
Closing figures are converted to the currency above at the exchange rate of the closing date. Source for the exchange rates: Sveriges Riksbank
The closing information is gathered directly from the companies or from Creditsafe.